CASI Pharmaceuticals, a US company formerly known as EntreMed, received CFDA permission to start a China Phase II trial of its proprietary drug for triple-negative breast cancer. The trial will be combined with a US Phase II trial, already in progress. CASI says that ENMD-2076, an orally-active, Aurora A/angiogenic kinase inhibitor, has a unique kinase selectivity profile and multiple mechanisms of action.
Help employers find you! Check out all the jobs and post your resume.
